Skip to main content

Table 1 Emetic risk groups according to MASCC

From: Overshadowing as prevention of anticipatory nausea and vomiting in pediatric cancer patients: study protocol for a randomized controlled trial

Risk Cytostatics
High Cisplatin, mechlorethamine, streptozocin, cyclophosphamide >1,500 mg/m2, carmustine, dacarbazin
  Oral: Hexamethylmelamine, procarbazine
Moderate Oxaliplatin, cytarabine >1,000 mg/m2, carboplatin, ifosfamide, cyclophosphamide <1,500 mg/m2, azacitidine, alemtuzumab, doxorubicin, daunorubicin, epirubicin, idarubicin, irinotecan, bendamustine, clofarabine
  Oral: Cyclophosphamide, temozolomide, vinorelbine, imatinib
Low Paclitaxel, docetaxel, mitoxantrone, topotecan, etoposide, pemetrexed, methotrexate, doxorubicin HCl liposome injection, temsirolimus, ixabepilone, mitomycin, gemcitabine, cytarabine <1,000 mg/m2, 5-fluorouracil, bortezomib, cetuximab, trastuzumab, catumaxomab, panitumumab
  Oral: Capecitabine, tegafur uracil, etoposide, sunitinib, fludarabine, everolimus, lapatinib, lenalidomide, thalidomide
Minimal Bleomycin, busulfan, cladribine, fludarabine, vinblastine, vincristine
  vinorelbine, bevacizumab
  Oral: chlorambucil, hydroxyurea, melphalan, methotrexate, 6-thioguanine
  gefitinib, sorafenib, erlotinib